A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors

Cytotherapy

Volumn 17, Issue 11, 2015, Pages 1594-1603

  Pérez Martínez, Antonio ^a   Fernández, Lucía ^b   Valentín, Jaime ^c   Martínez Romera, Isabel ^d   Corral, María Dolores ^d   Ramírez, Manuel ^e   Abad, Lorea ^e   Santamaría, Sandra ^e   González Vicent, Marta ^e   Sirvent, Sara ^e   Sevilla, Julián ^e   Vicario, José Luis ^f   de Prada, Inmaculada ^e   Diaz, Miguel Ángel ^e  

^a HOSPITAL INFANTIL LA PAZ   (Spain)

^b Clinical Research Program   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^f Centro de Transfusiones de la Comunidad de Madrid ^*  (Spain)

Author keywords

Haplo identical stem cell transplantation; IL 15 stimulated NK cells; Pediatric solid tumors

Indexed keywords

INTERLEUKIN 15;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADOPTIVE TRANSFER; ADRENAL CORTEX CARCINOMA; ALLOIMMUNITY; ARTICLE; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; EWING SARCOMA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HAPLO IDENTICAL STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERLEUKIN 15 STIMULATED NATURAL KILLER CELL INFUSION; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OSTEOSARCOMA; PEDIATRIC REFRACTORY SOLID TUMOR; PEDIATRICS; PRIORITY JOURNAL; SAFETY; SARCOMA; SCHOOL CHILD; SOLID TUMOR; STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; DRUG EFFECTS; GRAFT VS HOST DISEASE; IMMUNOLOGY; NATURAL KILLER CELL; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; CHILD; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; NEOPLASMS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84942551827     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.07.011     Document Type: Article

References (51)

1. Miller J.S. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program 2013, 2013:247-253.
2. Koh C.Y., Welniak L.A., Murphy W.J. Adoptive cellular immunotherapy: NK cells and bone marrow transplantation. Histol Histopathol 2000, 15:1201-1210.
3. Lundqvist A., McCoy J.P., Samsel L., Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007, 109:3603-3606.
4. Ruggeri L., Mancusi A., Burchielli E., Capanni M., Carotti A., Aloisi T., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
5. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172:644-650.
6. Pérez-Martínez A., Leung W., Muñoz E., Iyengar R., Ramírez M., Vicario J.L., et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer 2009, 53:120-124.
7. Pérez-Martínez A., de Prada Vicente I., Fernández L., González-Vicent M., Valentín J., Martín R., et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol 2012, 40:882-891.
8. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
9. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010, 28:955-959.
10. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
11. Waldmann T.A. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol 2014, 10:1689-1701.
12. Conlon K.C., Lugli E., Welles H.C., Rosenberg S.A., Fojo A.T., Morris J.C., et al. Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. J Clin Oncol 2015, 33:74-82.
13. Schlegel P., Teltschik H.M., Pfeiffer M., Handgretinger R., Schumm M., Koscielniak E., et al. Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. Best Pract Res Clin Haematol 2011, 24:443-452.
14. Alpdogan O., Eng J.M., Muriglan S.J., Willis L.M., Hubbard V.M., Tjoe K.H., et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005, 105:865-873.
15. Zhang C., Zhang J., Niu J., Zhang J., Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008, 42:128-136.
16. Koehl U., Sörensen J., Esser R., Zimmermann S., Grüttner H.P., Tonn T., et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004, 33:261-266.
17. Stern M., Passweg J.R., Meyer-Monard S., Esser R., Tonn T., Soerensen J., et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013, 48:433-438.
18. Ruggeri L., Mancusi A., Burchielli E., Aversa F., Martelli M.F., Velardi A. Natural killer cell alloreactivity and haplo-identical Hematopoietic transplantation. Cytotherapy 2006, 8:554-558.
19. Iyengar R., Handgretinger R., Babarin-Dorner A., Leimig T., Otto M., Geiger T.L., et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003, 5:479-484.
20. Pfeiffer M.M., Schumm M., Müller I., Handgretinger R., Lang P. IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT. Leukemia 2012, 26:2435-2439.
21. Ladenstein R., Pötschger U., Le Deley M.C., Whelan J., Paulussen M., Oberlin O., et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010, 28:3284-3291.
22. Ahn Y.O., Weigel B., Verneris M.R. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res 2010, 16:3819-3821.
23. Cho D., Shook D.R., Shimasaki N., Chang Y.H., Fujisaki H., Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010, 16:3901-3909.
24. Sevilla J., González-Vicent M., Madero L., García-Sánchez F., Díaz M.A. Granulocyte colony-stimulating factor alone at 12 microg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant 2002, 30:417-420.
25. Pérez-Martínez A., González-Vicent M., Valentín J., Aleo E., Lassaletta A., Sevilla J., et al. Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplant 2012, 47:1419-1427.
26. Fernández L., Portugal R., Valentín J., Martín R., Maxwell H., González-Vicent M., et al. In vitro natural killer cell immunotherapy for medulloblastoma. Front Oncol 2013, 3:94.
27. Martin A.M., Kulski J.K., Gaudieri S., Witt C.S., Freitas E.M., Trowsdale J., et al. Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B. Gene 2004, 335:121-131.
28. Blomberg K., Granberg C., Hemmilä I., Lövgren T. Europium-labelled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J Immunol Methods 1986, 86:225-229.
29. Ruggeri L., Capanni M., Mancusi A., Aversa F., Martelli M.F., Velardi A. Natural killer cells as a therapeutic tool in mismatched transplantation. Best Pract Res Clin Haematol 2004, 17:427-438.
30. Novitzky N., Davison G.M., Hale G., Waldmann H. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. Transplantation 2002, 74:1551-1559.
31. Munker R., Schmid C., Madrigal J.A., Kolb H.J. An update on graft-versus-host and graft-versus-leukemia reactions: a summary of the sixth International Symposium held in Schloss Ellmau, Germany, January 22-24, 2004. Bone Marrow Transplant 2004, 34:767-780.
32. Storb R., Gyurkocza B., Storer B.E., Sorror M.L., Blume K., Niederwieser D., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013, 31:1530-1538.
33. Shah N.N., Baird K., Delbrook C.P., Fleisher T.A., Kohler M.E., Rampertaap S., et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 2015, 125:784-792.
34. Buddingh E.P., Schilham M.W., Ruslan S.E., Berghuis D., Szuhai K., Suurmond J., et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011, 60:575-586.
35. Tang F., Zhao L.T., Jiang Y., Ba de N., Cui L.X., He W. Activity of recombinant human interleukin-15 against tumor recurrence and metastasis in mice. Cell Mol Immunol 2008, 5:189-196.
36. Yang Q., Goding S.R., Hokland M.E., Basse P.H. Antitumor activity of NK cells. Immunol Res 2006, 36:13-25.
37. Chiossone L., Vitale C., Cottalasso F., Moretti S., Azzarone B., Moretta L., et al. Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood 2007, 109:3767-3775.
38. Pfeiffer M.M., Feuchtinger T., Teltschik H.M., Schumm M., Müller I., Handgretinger R., et al. Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica 2010, 95:1381-1388.
39. Schlegel P., Feuchtinger T., Nitschke-Gérard C., Eva Seidel U.J., Lang A.M., Kyzirakos C., et al. Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients. Bone Marrow Transplant 2015, (50 Suppl 2):S72-S76.
40. Wai L.E., Fujiki M., Takeda S., Martinez O.M., Krams S.M. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008, 85:145-149.
41. Wang H., Grzywacz B., Sukovich D., McCullar V., Cao Q., Lee A.B., et al. The unexpected effect of cyclosporin A on CD56+CD16 and CD56+CD16+ natural killer cell subpopulations. Blood 2007, 110:1530-1539.
42. Petersson E., Qi Z., Ekberg H., Ostraat O., Dohlsten M., Hedlund G. Activation of alloreactive natural killer cells is resistant to cyclosporine. Transplantation 1997, 63:1138-1144.
43. Eissens D.N., Van Der Meer A., Van Cranenbroek B., Preijers F.W., Joosten I. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype. Am J Transplant 2010, 10:1981-1990.
44. Shao-Hsien C., Lang I., Gunn H., Lydyard P. Effect of in vitro cyclosporin. A treatment on human natural and antibody-dependent cell-mediated cytotoxicity. Transplantation 1983, 35:127-129.
45. Introna M., Allavena P., Spreafico F., Mantovani A. Inhibition of human natural killer activity by cyclosporin A. Transplantation 1981, 31:113-116.
46. Morteau O., Blundell S., Chakera A., Bennett S., Christou C.M., Mason P.D., et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS One 2010, 5:e13294.
47. Wasik M., Gorski A., Stepien-Sopniewska B., Lagodzinski Z. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. Transplantation 1991, 51:268-270.
48. Meehan A.C., Mifsud N.A., Nguyen T.H., Levvey B.J., Snell G.I., Kotsimbos T.C., et al. Impact of commonly used transplant immunosuppressive drugs on human NK cell function is dependent upon stimulation condition. PLoS One 2013, 8:e60144.
49. Ohata K., Espinoza J.L., Lu X., Kondo Y., Nakao S. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant 2011, 17:205-213.
50. De Maria A., Fogli M., Costa P., Murdaca G., Puppo F., Mavilio D., et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003, 33:2410-2418.
51. Lowe E.J., Turner V., Handgretinger R., Horwitz E.M., Benaim E., Hale G.A., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical pediatric bone marrow transplantation. Br J Haematol 2003, 123:323-326.